COSYREL – an efficient fixed combination for treatment of hypertension, stable ISHD and heart failure
Authors:
Jiří Widimský
Authors‘ workplace:
III. interní klinika 1. LF UK a VFN v Praze
Published in:
Vnitř Lék 2017; 63(10): 667-671
Category:
Reviews
Overview
Fixed combinations of two or three drugs are being frequently used in cardiovascular diseases. This approach markedly increases adherence of the patients to prolonged therapy and thus leads to better control of the diseases. Fixed combinations are often used in hypertension and coronary artery disease (CAD). Cosyrel is the first fixed combination of betablocker (bisoprolol fumarat) and ACE inhibitor (perindopril arginin) available in czech market. The advantage is availability in several concentrations (10 mg/10 mg, 10 mg/5 mg a 5 mg/10 mg a 5 mg/5 mg) , when first indicates bisoprolol dose and the second perindopril. This combination is indicated in arterial hypertension and/or in stable CAD (in patients after myocardial infarction or revascularisation) and/or in dosages 5 mg/5 mg and 5 mg/10 mg in patients with chronic heart failure with systolic dysfunction. This article aimed to evaluate briefly clinical characteristics of this fixed combination. Bisoprol and perindopril arginin have a lot of data indication their positive impact on CV risk and prognosis.
Key words:
bisoprolol – coronary artery disease – heart failure – hypertension – perindopril
Sources
1. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55(2): 399–407. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.139816>.
2. Hess G, Hill J, Lau H et al. Medication utilization patterns and hypertension-related expenditures among patiens who were switched from fixed-dose to free-combination antihypertensive therapy. PT 2008; 33(11): 652–666.
3. Filipovský J, Widimský J Jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785–801.
4. Corrao G, Nicotra F, Parodi A et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drug in daily life practice. Hypertension 2011; 58(4): 566–572. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.177592>.
5. Gradman AH, Parisé H, Lefebvre P et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61(2): 309–318. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.201566>.
6. Bussien JP, d´Amore TF, Perret L et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther 1986; 39(5): 554–558.
7. Hui Y, Dai Z, Chen X et al. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Chin Med J Engl 1995; 108(9): 678–681.
8. Taddei S. Bortolotto L. Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity. Am J Cardiovasc Drugs 2016; 16(5): 309–321. Dostupné z DOI: <http://dx.doi.org/10.1007/s40256–016–0173–4>.
9. Van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33(16): 2088–2097. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs075>.
10. Cosyrel. Souhrn údajů o přípravku. SUKL 2016. Dostupné z WWW: <http://www.sukl.cz/modules/medication/detail.php?code=0209912&tab=texts>.
11. Vítovec J, Špinar J. Diuretika a betablokátory v léčbě hypertenze. Interní Med 2012; 14(12): 458–460.
12. Vítovec J, Špinar J. Betapres – nová fixní kombinace pro preventivní kardiologii. Hypertenze a kardiovaskulární prevence 2014; 3(1): 30–32.
13. Poulter NR, Wedel H, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366(9489): 907–913.
14. The European trial On reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–788.
15. 15.Yusuf S, Sleight P, Pogue J et al. [Heart Outcomes Prevention Evaluation Study Investigators]. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342(3): 145–153. Erratum in 2000; 342(18): 1376. N Engl J Med 2000; 342(10):748.
16. Bertrand ME, Ferrari R, Remme WJ et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J 2015; 170(6): 1092–1098. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2015.08.018>.
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353(9146): 9–13.
18. Widimský J Jr, Widimský J et al. Hypertenze. 4. vyd. Triton: Praha 2014. ISBN 978–80–7387–811–5.
19. Widimský J, Widimský J Jr. Farmakoterapie hypertenze. Maxdorf: Praha 2016. ISBN 978–80–7345–477–7.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 10
Most read in this issue
- COSYREL – an efficient fixed combination for treatment of hypertension, stable ISHD and heart failure
- Surgical treatment of aortic root aneurysm: comparison of Bentall procedure and David reimplantation of aortic valve
- Physical activity – the Holy Grail of modern medicine?
- Endocrine orbitopathy: the present view of a clinical endocrinologist